Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Somatosensory Disorders D020886 1 associated lipids
Orthostatic Intolerance D054971 1 associated lipids
Sleep Disorders, Intrinsic D020919 1 associated lipids
Headache Disorders, Secondary D051271 1 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Substance-Related Disorders D019966 2 associated lipids
Ocular Hypotension D015814 2 associated lipids
Vascular System Injuries D057772 2 associated lipids
Schistosomiasis japonica D012554 3 associated lipids
Bulimia D002032 3 associated lipids
Acute Pain D059787 3 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Urinary Bladder Diseases D001745 4 associated lipids
Fibromyalgia D005356 4 associated lipids
Impotence, Vasculogenic D018783 4 associated lipids
Urinary Incontinence D014549 4 associated lipids
Picornaviridae Infections D010850 4 associated lipids
Pregnancy, Ectopic D011271 5 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Brain Concussion D001924 5 associated lipids
Muscle Spasticity D009128 5 associated lipids
Sleep Deprivation D012892 5 associated lipids
Brain Damage, Chronic D001925 6 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Anorexia D000855 8 associated lipids
Morphine Dependence D009021 9 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Learning Disorders D007859 11 associated lipids
Shock, Septic D012772 11 associated lipids
Overweight D050177 11 associated lipids
Hyperkinesis D006948 11 associated lipids
Hepatitis D006505 11 associated lipids
Migraine Disorders D008881 11 associated lipids
Hypertension, Portal D006975 12 associated lipids
Neoplasms D009369 13 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Bradycardia D001919 13 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Cardiomyopathy, Dilated D002311 15 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Celiac Disease D002446 16 associated lipids
Parkinson Disease, Secondary D010302 17 associated lipids
Bronchial Spasm D001986 18 associated lipids
Mycoses D009181 18 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Cough D003371 19 associated lipids
Hypothermia D007035 19 associated lipids
Peptic Ulcer D010437 19 associated lipids
Ataxia D001259 20 associated lipids
Brain Edema D001929 20 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Breast Neoplasms D001943 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hyperemia D006940 25 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Hyperinsulinism D006946 27 associated lipids
Endotoxemia D019446 27 associated lipids
Neuralgia D009437 28 associated lipids
Obesity D009765 29 associated lipids
Catalepsy D002375 30 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Memory Disorders D008569 33 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Fever D005334 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Epilepsy D004827 35 associated lipids
Nervous System Diseases D009422 37 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Hypotension D007022 41 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Fatty Liver D005234 48 associated lipids
Nerve Degeneration D009410 53 associated lipids
Pain D010146 64 associated lipids
Reperfusion Injury D015427 65 associated lipids
Neuroblastoma D009447 66 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Stomach Ulcer D013276 75 associated lipids
Alzheimer Disease D000544 76 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Insulin Resistance D007333 99 associated lipids
Weight Gain D015430 101 associated lipids
Glioma D005910 112 associated lipids
Hypertension D006973 115 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Jergas B et al. O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus. 2014 Naunyn Schmiedebergs Arch. Pharmacol. pmid:24853577
Pietrzak RH et al. Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors. 2014 Neuropsychopharmacology pmid:24820537
Scotchie JG et al. Endocannabinoid regulation in human endometrium across the menstrual cycle. 2015 Reprod Sci pmid:24819878
pmid:24813296
Ravi J et al. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. 2014 Oncotarget pmid:24811863
Park SW et al. Anticancer effects of anandamide on head and neck squamous cell carcinoma cells via the production of receptor-independent reactive oxygen species. 2015 Head Neck pmid:24797795
pmid:24788457
Hama AT et al. Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain. 2014 PLoS ONE pmid:24788435
Al Kury LT et al. Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes. 2014 Br. J. Pharmacol. pmid:24758718
pmid:24747871
Ohno-Shosaku T and Kano M Endocannabinoid-mediated retrograde modulation of synaptic transmission. 2014 Curr. Opin. Neurobiol. pmid:24747340
pmid:24717329
Nader J et al. Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. 2014 Neuropharmacology pmid:24709540
pmid:24705535
Kaczocha M et al. Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. 2014 PLoS ONE pmid:24705380
Sun LJ et al. Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication. 2014 Int. J. Infect. Dis. pmid:24704332
Jackson AR et al. Anandamide attenuates Th-17 cell-mediated delayed-type hypersensitivity response by triggering IL-10 production and consequent microRNA induction. 2014 PLoS ONE pmid:24699635
pmid:24687644
Baranowska-Kuczko M et al. Mechanisms of endothelium-dependent relaxation evoked by anandamide in isolated human pulmonary arteries. 2014 Naunyn Schmiedebergs Arch. Pharmacol. pmid:24682422
pmid:24674601
pmid:24671517
Smaga I et al. Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. 2014 Neurotox Res pmid:24652522
Basavarajappa BS et al. Elevation of endogenous anandamide impairs LTP, learning, and memory through CB1 receptor signaling in mice. 2014 Hippocampus pmid:24648181
Yu S et al. Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in the brain. 2014 J. Biol. Chem. pmid:24644281
Engeli S et al. Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects. 2014 Obesity (Silver Spring) pmid:24616451
Gamage TF et al. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. 2014 Behav Pharmacol pmid:24603340
Kwilasz AJ et al. Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats. 2014 Behav Pharmacol pmid:24583930
Chianese R et al. Hypothalamus-pituitary axis: an obligatory target for endocannabinoids to inhibit steroidogenesis in frog testis. 2014 Gen. Comp. Endocrinol. pmid:24566122
Okura D et al. The endocannabinoid anandamide inhibits voltage-gated sodium channels Nav1.2, Nav1.6, Nav1.7, and Nav1.8 in Xenopus oocytes. 2014 Anesth. Analg. pmid:24557103
Sanson B et al. Crystallographic study of FABP5 as an intracellular endocannabinoid transporter. 2014 Acta Crystallogr. D Biol. Crystallogr. pmid:24531463
Chiou LC et al. Targeting the cannabinoid system for pain relief? 2013 Acta Anaesthesiol Taiwan pmid:24529672
Pava MJ et al. Endocannabinoid modulation of cortical up-states and NREM sleep. 2014 PLoS ONE pmid:24520411
Rapino C et al. Endocannabinoids as biomarkers of human reproduction. 2014 Jul-Aug Hum. Reprod. Update pmid:24516083
Zheng Y et al. Dexamethasone alleviates motion sickness in rats in part by enhancing the endocannabinoid system. 2014 Eur. J. Pharmacol. pmid:24508383
pmid:24508153
Rea K et al. Microinjection of 2-arachidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state. 2014 Eur. J. Neurosci. pmid:24494683
Sousa-Valente J et al. Anandamide in primary sensory neurons: too much of a good thing? 2014 Eur. J. Neurosci. pmid:24494681
Sagie S et al. [Short-and long-term effects of cannabinoids on memory, cognition and mental illness]. 2013 Harefuah pmid:24483000
Al Kury LT et al. Effects of endogenous cannabinoid anandamide on excitation-contraction coupling in rat ventricular myocytes. 2014 Cell Calcium pmid:24472666
Björklund E et al. Ketoconazole inhibits the cellular uptake of anandamide via inhibition of FAAH at pharmacologically relevant concentrations. 2014 PLoS ONE pmid:24466356
Kono M et al. Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors. 2014 Bioorg. Med. Chem. pmid:24440478
pmid:24438603
Thieme U et al. Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans. 2014 Jan-Feb Drug Test Anal pmid:24424856
Krishnan G and Chatterjee N Endocannabinoids affect innate immunity of Muller glia during HIV-1 Tat cytotoxicity. 2014 Mol. Cell. Neurosci. pmid:24418364
Leo LM et al. Age-dependent relevance of endogenous 5-lipoxygenase derivatives in anxiety-like behavior in mice. 2014 PLoS ONE pmid:24416334
Nicolussi S et al. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. 2014 Pharmacol. Res. pmid:24412246
Mahavadi S et al. Inhibitory signaling by CB1 receptors in smooth muscle mediated by GRK5/β-arrestin activation of ERK1/2 and Src kinase. 2014 Am. J. Physiol. Gastrointest. Liver Physiol. pmid:24407588
Fowler CJ Has FLAT fallen flat? 2014 Trends Pharmacol. Sci. pmid:24398120
Carr RL et al. Low level chlorpyrifos exposure increases anandamide accumulation in juvenile rat brain in the absence of brain cholinesterase inhibition. 2014 Neurotoxicology pmid:24373905
Gesell FK et al. Alterations of endocannabinoids in cerebrospinal fluid of dogs with epileptic seizure disorder. 2013 BMC Vet. Res. pmid:24370333
Oleson EB et al. Cannabinoid receptor activation shifts temporally engendered patterns of dopamine release. 2014 Neuropsychopharmacology pmid:24345819
Luce V et al. The inhibitory effect of anandamide on oxytocin and vasopressin secretion from neurohypophysis is mediated by nitric oxide. 2014 Regul. Pept. pmid:24342802
Bystrowska B et al. Changes in endocannabinoid and N-acylethanolamine levels in rat brain structures following cocaine self-administration and extinction training. 2014 Prog. Neuropsychopharmacol. Biol. Psychiatry pmid:24334211
Gunduz-Cinar O et al. Amygdala FAAH and anandamide: mediating protection and recovery from stress. 2013 Trends Pharmacol. Sci. pmid:24325918
Vavilin VA et al. Cytochrome P450 4F2 polymorphism in patients with liver cirrhosis. 2013 Bull. Exp. Biol. Med. pmid:24319743
Jackson AR et al. Characterization of endocannabinoid-mediated induction of myeloid-derived suppressor cells involving mast cells and MCP-1. 2014 J. Leukoc. Biol. pmid:24319288
Martinez-Vargas M et al. Does the neuroprotective role of anandamide display diurnal variations? 2013 Int J Mol Sci pmid:24287910
Hoyer FF et al. Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice. 2014 J. Mol. Cell. Cardiol. pmid:24286707
Schaefer C et al. Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. 2014 Eur Arch Psychiatry Clin Neurosci pmid:24253425
Harvey BS et al. Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. 2014 Cytokine pmid:24238999
Leung K et al. Role of FAAH-like anandamide transporter in anandamide inactivation. 2013 PLoS ONE pmid:24223930
Battista N et al. Analytical approaches for the determination of phytocannabinoids and endocannabinoids in human matrices. 2014 Jan-Feb Drug Test Anal pmid:24218186
Liu J et al. Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase. 2013 Proc. Natl. Acad. Sci. U.S.A. pmid:24191036
Wenzel D et al. Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction. 2013 Proc. Natl. Acad. Sci. U.S.A. pmid:24167249
Desroches J et al. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. 2014 Neuropharmacology pmid:24148808
Burston JJ and Woodhams SG Endocannabinoid system and pain: an introduction. 2014 Proc Nutr Soc pmid:24148358
Pertwee RG Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. 2014 Proc Nutr Soc pmid:24135210
Stanley CP et al. Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes. 2013 Eur. J. Pharmacol. pmid:24120371
Marichal-Cancino BA et al. Role of pre-junctional CB1, but not CB2 , TRPV1 or GPR55 receptors in anandamide-induced inhibition of the vasodepressor sensory CGRPergic outflow in pithed rats. 2014 Basic Clin. Pharmacol. Toxicol. pmid:24118786
Bernabò N et al. Systems biology analysis of the endocannabinoid system reveals a scale-free network with distinct roles for anandamide and 2-arachidonoylglycerol. 2013 OMICS pmid:24117401
pmid:24117326
pmid:24114173
Malenczyk K et al. CB1 cannabinoid receptors couple to focal adhesion kinase to control insulin release. 2013 J. Biol. Chem. pmid:24089517
Alvheim AR et al. Dietary linoleic acid elevates the endocannabinoids 2-AG and anandamide and promotes weight gain in mice fed a low fat diet. 2014 Lipids pmid:24081493
Marichal-Cancino BA et al. Analysis of anandamide- and lysophosphatidylinositol-induced inhibition of the vasopressor responses produced by sympathetic stimulation or noradrenaline in pithed rats. 2013 Eur. J. Pharmacol. pmid:24076186
Fonseca BM et al. The endocannabinoid anandamide induces apoptosis of rat decidual cells through a mechanism involving ceramide synthesis and p38 MAPK activation. 2013 Apoptosis pmid:24048885
Limebeer CL et al. Attenuation of anticipatory nausea in a rat model of contextually elicited conditioned gaping by enhancement of the endocannabinoid system. 2014 Psychopharmacology (Berl.) pmid:24043345
Adinolfi B et al. Anticancer activity of anandamide in human cutaneous melanoma cells. 2013 Eur. J. Pharmacol. pmid:24041928
pmid:24037493
Hill MN et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. 2013 Psychoneuroendocrinology pmid:24035186
Akerman S et al. Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and "triptan" receptors: implications in migraine. 2013 J. Neurosci. pmid:24027286
Brocato B et al. Endocannabinoid crosstalk between placenta and maternal fat in a baboon model (Papio spp.) of obesity. 2013 Placenta pmid:24008071
O'Brien LD et al. Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus). 2013 Br. J. Pharmacol. pmid:23991698
Gervasi MG et al. Anandamide levels fluctuate in the bovine oviduct during the oestrous cycle. 2013 PLoS ONE pmid:23977311
Jourdan T et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. 2013 Nat. Med. pmid:23955712
Piomelli D More surprises lying ahead. The endocannabinoids keep us guessing. 2014 Neuropharmacology pmid:23954677
pmid:23948212
Krumbholz A et al. Diagnostic value of concentration profiles of glucocorticosteroids and endocannabinoids in hair. 2013 Ther Drug Monit pmid:23942543
Derbenev AV and Smith BN Dexamethasone rapidly increases GABA release in the dorsal motor nucleus of the vagus via retrograde messenger-mediated enhancement of TRPV1 activity. 2013 PLoS ONE pmid:23936221
Maione S et al. Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics. 2013 Pharmacol. Res. pmid:23911581
Khlaifia A et al. Anandamide, cannabinoid type 1 receptor, and NMDA receptor activation mediate non-Hebbian presynaptically expressed long-term depression at the first central synapse for visceral afferent fibers. 2013 J. Neurosci. pmid:23904599
Ilayan E et al. Do cannabinoids exhibit a tyramine-like effect? 2013 Naunyn Schmiedebergs Arch. Pharmacol. pmid:23900610
Lisboa SF et al. Complex interaction between anandamide and the nitrergic system in the dorsolateral periaqueductal gray to modulate anxiety-like behavior in rats. 2013 Neuropharmacology pmid:23899460
Coppola M and Mondola R Palmitoylethanolamide: from endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence. 2013 Med. Hypotheses pmid:23896215
Ruginsk SG et al. Anandamide modulates the neuroendocrine responses induced by extracellular volume expansion. 2013 Clin. Exp. Pharmacol. Physiol. pmid:23875874
Citraro R et al. CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. 2013 Epilepsy Res. pmid:23860329
Iannotti FA et al. Analysis of the "endocannabinoidome" in peripheral tissues of obese Zucker rats. 2013 Prostaglandins Leukot. Essent. Fatty Acids pmid:23830028
Silvestri C et al. Anandamide-derived prostamide F2α negatively regulates adipogenesis. 2013 J. Biol. Chem. pmid:23801328
Brantl SA et al. Mechanism of platelet activation induced by endocannabinoids in blood and plasma. 2014 Platelets pmid:23789792
Carr RL et al. Induction of endocannabinoid levels in juvenile rat brain following developmental chlorpyrifos exposure. 2013 Toxicol. Sci. pmid:23761300